Jennifer Brown, MD, PhD, completed a BSc and MSc in molecular biophysics and biochemistry at Yale University in New Haven, CT, before undertaking a medical degree and a PhD in molecular genetics, at Harvard Medical School in Boston, MA. Prof. Brown completed an internship and residency in internal medicine at Massachusetts General Hospital followed by a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute in Boston, MA. She is currently a Professor of Medicine at Harvard Medical School and Director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute.
Speaking on chronic lymphocytic leukemia
Prof. Brown’s research interests are centered around the development of novel targeted therapeutics for chronic lymphocytic leukemia (CLL). She was highly involved in the clinical development of idelalisib and ibrutinib and has also carried out research in CLL genomics identifying specific CLL subgroups and resistance mechanisms.
Furthermore, Prof. Brown has a research interest in characterizing the heritability of CLL through a greater understanding the genetics of familial CLL. She has published over 150 papers, predominantly in CLL, and has presented her work at numerous national and international conferences.